Skip to content
Telehealth Graded
State guide

Arizona, AHCCCS and GLP-1s

No rule changed in Arizona this year. What happened instead is that the cost of changing one was worked out in public, twice, by the legislature's own budget staff. A November 2025 briefing reported what the plan covering state employees and retirees already spends on these drugs and what it would spend if the weight indication were added. A fiscal note did the same arithmetic for the Medicaid program. Then a study committee wrapped up in December with three recommendations, none of which requires anybody to pay for a prescription.

Every source on this page was read first-hand in September 2026, and each one below carries the date printed on the document itself.

3
documents cited
7
sourced facts
3
primary sources

What changed, and what the document says

  1. The state employee plan, on weight loss

    Not covered

    The plan that covers active and retired state workers pays for several GLP-1s, and excludes the indication most shoppers are asking about.

    The plan does not cover any drug solely for the purpose of weight loss/obesity.

    Arizona Joint Legislative Budget CommitteeNovember 25, 2025

  2. What it spends anyway

    Context

    The exclusion is about the indication, not the molecule — the same plan's diabetes spending on this drug class runs into eight figures.

    In Plan Year 2025, spending on GLP-1s was $28 M.

    Arizona Joint Legislative Budget CommitteeNovember 25, 2025

  3. Per person, per year

    Context

    Budget staff published the per-member figure rather than only the total, which is the number a cash shopper can actually compare against.

    Average annual amount paid per member was $8,637.

    Arizona Joint Legislative Budget CommitteeNovember 25, 2025

  4. Medicaid's rule, in the agency's own slide

    Not covered

    The Medicaid agency told the committee directly where it stands, and the committee printed the slide in its final report.

    AHCCCS currently does not cover GLP-1 for the treatment of obesity.

    Arizona State Legislature, Obesity Treatment Study CommitteeDecember 2025

  5. The single carve-out the agency names

    Conditions apply

    One drug, one purpose, and a prior authorization — the heart-risk indication survives where the weight indication does not.

    AHCCCS also covers 1 GLP-1 Receptor Agonist (Wegovy) in specific circumstances to reduce the risk of major adverse cardiovascular events when medically necessary and approved via prior authorization.

    Arizona State Legislature, Obesity Treatment Study CommitteeDecember 2025

  6. What the change was priced at

    Context

    A fiscal note on a bill that would have required comprehensive obesity coverage put a range on it and then warned readers about the range.

    we estimate the full-year cost of providing coverage of anti-obesity medication could range from $962.9 million-$2.5 billion on a Total Funds basis

    Arizona Joint Legislative Budget Committee Staff2/20/24

  7. What the committee asked for in the end

    Context

    Three recommendations came out of the hearings. The first one is a definition, not a benefit.

    Officially recognize obesity as a chronic disease.

    Arizona State Legislature, Obesity Treatment Study CommitteeDecember 2025

Which of these companies serve Arizona?

Of the 257 companies we grade, 25 publish a list of the states they are licensed in. We checked 229 more and found no such list on any page we read; 3 we have not checked either way.

20 of those lists name Arizona: Red Mountain Weight Loss, Gala Health, Care Bare Rx, Vita Bella, TelePeptide, Wisp, WePeptideRx, Ways2Well, TeleClinic, Tyde Wellness, Willow, ZYP Medical, The Virtual NP, VevaRx, Trimi, Enhance MD, HumeCare+, Rx.com, Mojoon and Peak Wellness. That is a licensure claim each company makes about itself, not something we checked with a state board.

A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.

Sources

Each document below was fetched and read on the date shown beside it, which is the date printed on the document — not always the date in its web address. All of them were read in September 2026, the same session as the rest of this page.

Nothing on this page is medical advice, and nobody here is a clinician. Coverage rules change; check the linked document before you rely on it.